0000899243-21-000680.txt : 20210106 0000899243-21-000680.hdr.sgml : 20210106 20210106160508 ACCESSION NUMBER: 0000899243-21-000680 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210104 FILED AS OF DATE: 20210106 DATE AS OF CHANGE: 20210106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly Timothy P CENTRAL INDEX KEY: 0001754067 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38433 FILM NUMBER: 21510492 MAIL ADDRESS: STREET 1: C/O HOMOLOGY MEDICINES, INC. STREET 2: ONE PATRIOTS PARK CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Homology Medicines, Inc. CENTRAL INDEX KEY: 0001661998 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473468154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE PATRIOTS PARK CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-301-7277 MAIL ADDRESS: STREET 1: ONE PATRIOTS PARK CITY: BEDFORD STATE: MA ZIP: 01730 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-04 0 0001661998 Homology Medicines, Inc. FIXX 0001754067 Kelly Timothy P C/O HOMOLOGY MEDICINES, INC. ONE PATRIOTS PARK BEDFORD MA 01730 0 1 0 0 See Remarks Common Stock 2021-01-04 4 M 0 2000 6.6314 A 2000 D Common Stock 2021-01-04 4 M 0 2000 2.8947 A 4000 D Common Stock 2021-01-04 4 S 0 4000 11.4957 D 0 D Employee Stock Options 6.6314 2021-01-04 4 M 0 2000 0.00 D 2027-12-06 Common Stock 2000 45500 D Employee Stock Options 2.8947 2021-01-04 4 M 0 2000 0.00 D 2027-09-06 Common Stock 2000 36001 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.19 to $11.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018, so that such option will become fully vested on January 1, 2022. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was May 30, 2017. Chief Technical Operations Officer /s/ Bradford Smith, Attorney-in-Fact for Timothy P. Kelly 2021-01-06